Genelux Corp (GNLX)
Health Care · Nasdaq
Genelux is a late clinical-stage biopharmaceutical company developing oncolytic vaccinia virus immunotherapies designed to selectively kill tumor cells and trigger personalized anti-tumor immune responses.
What Genelux Corp does
Genelux is a late clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for aggressive and difficult-to-treat cancers. The company's lead candidate, Olvi-Vec, is a proprietary modified vaccinia virus designed to selectively kill tumor cells and induce patient-specific immune responses against tumor neoantigens. Olvi-Vec is being evaluated in three clinical trials: a Phase 3 registrational trial for platinum-resistant ovarian cancer, a Phase 2 trial for recurrent non-small cell lung cancer, and a Phase 1b/2 trial in China for recurrent small cell lung cancer. Genelux operates its own cGMP manufacturing facility in San Diego, California and has licensed development rights in China to partner Newsoara.
Themes: ["oncolytic viruses / oncolytic immunotherapy","cancer immunotherapy","platinum-resistant ovarian cancer","non-small cell lung cancer (NSCLC)","small cell lung cancer (SCLC)","personalized / neoantigen-based immunotherapy"]
Fundamentals
- Price$3.03 as of 2026-07-10 close
- Market cap$136M as of 2026-07-13
- 1-year return-11.9% as of 2026-07-10 close
- Net margin-115587.5% as of 2026-07-13
- ROE-174.6% as of 2026-07-13
- Debt / equity0.00 as of 2026-07-13
- Revenue growth (YoY)-91.0% as of 2026-07-13
- Revenue CAGR (3y)-91.0% SEC XBRL
- Beta0.55 as of 2026-07-13
Key risks (from latest filing)
["Lead product Olvi-Vec is in late-stage clinical development with no approved products yet; regulatory approval is uncertain and clinical trial failure would be existential.","Company is currently pre-revenue with substantial operating losses ($9.2M in Q1 2026) and a net margin of -115,588%, making it dependent on equity financing and extremely cash-constrained.","Oncolytic virus therapies are novel and represent significant technical and manufacturing complexity; manufacturing scale-up and cGMP compliance risks could delay commercialization or increase costs."]
Competitors & peers
- Replimune (REPL)
- Turnstone Biologics
- SillaJen
- Western Oncolytics
- Targovax
Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.